NASDAQ: IMRX · Life Sciences · 3 alerts · CIK 1790340
Share price
$3.52Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Immuneering Corp filings on SEC EDGAR ↗
Immuneering Corp is a late-stage clinical oncology company focused on developing its lead candidate, atebimetinib (IMM-1-104), for first-line pancreatic cancer. The company reports a history of significant net losses and expects to require substantial additional capital to fund its ongoing Phase 1/2a and MAPKeeper 301 registrational trials.
Immuneering reported Q3 2026 financial results and provided updates on its clinical pipeline, including the extension of follow-up for its Phase 2 pancreatic cancer trial as patients are living longer than projected. The company also announced that enrollment for its pivotal Phase 3 MAPKeeper 301 trial is ahead of schedule, allowing for an expanded enrollment target of 570 patients and a potential acceleration of the mid-2028 topline data readout.
“We are thrilled to share that follow-up in our Phase 2 trial in first-line pancreatic cancer is being extended because patients are living longer than projected. We now plan to provide an update on topline data from the atebimetinib + mGnP arm of that trial in the first half of 2027. We are also excited to report that enrollment in our pivotal Phase 3 MAPKeeper 301 trial is ahead of schedule. This strong momentum enables us to expand the enrollment target and potentially accelerate our expected mid-2028 topline data readout. We have updated our cash runway guidance to the fourth quarter of 2028 to reflect our Phase 2 extension, accelerated and expanded Phase 3 enrollment, and commercial readiness activities.”